Google
Trusted Resources: Evidence & Education
Scientific literature and patient education texts
Shared Decision Making for Hydroxyurea Treatment Initiation in Children With Sickle Cell Anemia
source: Pediatric Blood & Cancer
year: 2015
authors: Lori E. Crosby, Lisa M. Shook, Russell E. Ware, William B. Brinkman
summary/abstract:Clinical trials have demonstrated hydroxyurea’s efficacy in improving health outcomes for children with sickle cell anemia (SCA) who have medical complications. New NHLBI clinical guidelines will recommend offering hydroxyurea to young patients regardless of clinical severity. Shared decision making may be an effective approach for implementing this practice change. Decision aids that help patients/parents feel empowered to make this decision and help providers feel comfortable in discussing hydroxyurea as a preventive treatment may facilitate shared discussions between families and providers. We recommend six strategies providers can use to facilitate these discussions while decision aids and tools are being developed.
organization: Cincinnati Children's Hospital Medical Center, USA; University of Cincinnati College of Medicine, USADOI: 10.1002/pbc.25124
read more full text
+myBinderRelated Content
-
Targeted hydroxyurea education after an emergency department visit increases hydroxyurea use in children with sickle...Objective: To evaluate the impact of an...
-
Guidelines for the use of hydroxycarbamide in children and adults with sickle cell disease: A British society for ha...Sickle cell disease (SCD) is a generic t...
-
ATS Releases Guidelines for Home Oxygen Therapy in Children With Sickle Cell DiseaseThe American Thoracic Society (ATS) rele...
-
Is Your Child the Right Candidate for Hydroxyureahttps://www.youtube.com/watch?v=vMvC5rVH...
-
ADDMEDICA receives FDA-approval for orphan drug Siklos®, first and sole hydroxyurea-based treatment for paediatric ...ADDMEDICA has announced that the...
-
SCD Patients Receiving Hydroxyurea in the U.S. Still Face Many ChallengesPeople with sickle cell disease (SCD) tr...
-
Siklos®, the first and only hydroxyurea-based treatment for pediatric patients with sickle cell anemia, now availab...Medunik USA, a company dedicated to impr...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Support for this site is provided by
This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.